Similar articles

• A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.

  Hässler F, Glaser T, Pap AF, Beneke M, Diefenbacher A, Reis O; Zuclopenthixol Disruptive Behavior Study Group. Hässler F, et al. Pharmacopsychiatry. 2008 Nov;41(6):232-9. doi: 10.1055/s-0028-1082072. Epub 2008 Dec 9. Pharmacopsychiatry. 2008. PMID: 19067260 Clinical Trial.
• Isofloxythepin in restless oligophrenic children.

  Zapletálek M, Hametová M, Rýdlová E. Zapletálek M, et al. Act Nerv Super (Praha). 1989 Dec;31(4):265. Act Nerv Super (Praha). 1989. PMID: 2576920 No abstract available.
• [Clopixol: new possibilities in therapy of mental disorders (a review of clinical studies)].

  Litvintsev SV, Reznik AM, Arbuzov AL, Barkov DA. Litvintsev SV, et al. Voen Med Zh. 2002 Mar;323(3):42-7. Voen Med Zh. 2002. PMID: 11965908 Review. Russian. No abstract available.
• Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.

  Holmes C, Wilkinson D, Dean C, Clare C, El-Okl M, Hensford C, Moghul S. Holmes C, et al. Int J Geriatr Psychiatry. 2007 Apr;22(4):380-1. doi: 10.1002/gps.1667. Int J Geriatr Psychiatry. 2007. PMID: 17380475 Clinical Trial. No abstract available.
• Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases.

  Boyd RD. Boyd RD. Am J Ment Retard. 1993 Jul;98(1):143-55. Am J Ment Retard. 1993. PMID: 8103996 Review.